Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Delayed Quote. Delayed NASDAQ OMX COPENHAGEN - 10/23 10:59:47 am
445.25 DKK   +0.26%
10/16NOVO NORDISK : Buy rating from Goldman Sachs
MD
10/14NOVO NORDISK : Buy rating from JP Morgan
MD
10/12NOVO NORDISK : Credit Suisse gives a Buy rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

NOVO NORDISK : UBS remains Neutral

share with twitter share with LinkedIn share with facebook
08/18/2020 | 05:44am EDT

In his latest research note, analyst Michael Leuchten confirms his recommendation. The broker UBS is keeping its Neutral rating. Previously set at DKK 425, the target price has been slightly modified to DKK 415.

© MarketScreener with dpa-AFX Analyser 2020

Stocks mentioned in the article
ChangeLast1st jan.
NOVO NORDISK A/S 0.26% 445.25 Delayed Quote.15.16%
UBS GROUP AG 0.13% 11.26 Delayed Quote.-7.89%
share with twitter share with LinkedIn share with facebook
All news about NOVO NORDISK A/S
10/16NOVO NORDISK : Buy rating from Goldman Sachs
MD
10/14NOVO NORDISK : Buy rating from JP Morgan
MD
10/12NOVO NORDISK : Credit Suisse gives a Buy rating
MD
10/12NOVO NORDISK A/S : Bavarian Nordic Announces Appointment of Anu Helena Kerns as ..
AQ
10/12NOVO NORDISK A/S : Conference call regarding updated 2020 outlook 9 October 2020
PU
10/12NOVO NORDISK A/S : Alexander Mann Solutions partners with Novo Nordisk to suppor..
AQ
10/12NOVO NORDISK A/S : – Share repurchase programme
AQ
10/09EUROPE : European stocks rack up second week of gains, Pandora leaps
RE
10/09NOVO NORDISK : Credit Suisse gives a Buy rating
MD
10/09GLOBAL MARKETS LIVE : Acquisitions, acquisitions, acquisitions
More news
Financials
Sales 2020 128 B 20 361 M 20 361 M
Net income 2020 42 192 M 6 727 M 6 727 M
Net cash 2020 10 613 M 1 692 M 1 692 M
P/E ratio 2020 24,7x
Yield 2020 2,02%
Capitalization 1 035 B 165 B 165 B
EV / Sales 2020 8,02x
EV / Sales 2021 7,50x
Nbr of Employees 43 526
Free-Float 75,1%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 447,63 DKK
Last Close Price 445,25 DKK
Spread / Highest target 22,4%
Spread / Average Target 0,53%
Spread / Lowest Target -31,5%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S15.16%164 690
JOHNSON & JOHNSON-0.43%381 970
ROCHE HOLDING AG-5.33%280 343
PFIZER INC.-2.55%207 994
MERCK & CO., INC.-12.23%200 341
NOVARTIS AG-16.62%186 175